BSE Regulatory Approval

Management Change

BSE Management Change

BSE Limited disclosed SEBI's approval for Shri Ashutosh Singh's appointment as Executive Director for Vertical 3 (Business). The appointment is effective upon joining, subject to shareholder ratification.

Other Announcement

BSE Other Announcement

BSE Limited has received an ESG rating of 70 and a Core ESG rating of 72 from NSE Sustainability Ratings & Analytics. The rating was independently prepared for FY 2025-26.

Board Meeting Date

BSE Board Meeting Date

BSE Limited will hold a board meeting on November 4, 2026, to consider and approve its standalone and consolidated unaudited financial results for the half-year ended September 2026.

Acquisition

BSE Acquisition Worth ₹9.28 Cr

BSE Limited acquired additional equity in India International Bullion Holding IFSC Limited (IIBH) via a rights issue for ₹9.28 Crore, increasing its stake to 5.54%.

Value

₹9.28 Cr

Other Announcement

BSE Other Announcement

BSE Limited received an ESG rating of 69 and Core ESG rating of 72 for FY 2025-26 from CRISIL ESG.

Annual General Meeting

BSE Annual General Meeting

BSE Limited held its 21st Annual General Meeting on August 19, 2026. The proceedings covered ordinary business, including the declaration of a final dividend.

Regulatory ApprovalShalby Ltd SHALBYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Regulatory ApprovalElantas Beck India Ltd ELANTASAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Regulatory ApprovalKalyani Cast-Tech Ltd 544023Alfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Regulatory ApprovalMukka Proteins Ltd MUKKAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Regulatory ApprovalCanara Bank CANBKAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.